NCT01480310已完成1 期
A Phase Ia, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This is a Phase Ia, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in male and female healthy volunteers, aged 18-55 years, enrolled at a single study site in Canada.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Total body weight between 45 and 110 kg
- •Vital signs within the following ranges: oral body temperature of 35°C to 37.5°C, systolic blood pressure of 90 to 140 mmHg, diastolic blood pressure of 50 to 90 mmHg, and pulse rate of 45 to 100 bpm
- •Laboratory test parameters within normal reference ranges of the safety laboratory
- •Female subjects: Willing to use two effective methods of contraception from screening to a minimum of 4 months after the last dose of study drug. Reliable forms of contraception include oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical double-barrier methods, surgical hysterectomy, or vasectomy by male partner.
排除标准
- •Pregnant or lactating women
- •Administration of a live, attenuated vaccine within 30 days before Day 1 or anticipation that such a live attenuated vaccine will be required within 100 days of Day 1
- •Subjects may receive influenza vaccination only during influenza season (approximately October to March). Subjects must not receive live attenuated influenza vaccine within 30 days prior to Day 1 or at any time during the study.
- •Any major illness within 30 days prior to Day 1
- •Clinically significant illness requiring treatment within 14 days prior to Day 1
- •History of clinically significant ECG abnormalities or a known family history of cardiac conduction system disease
- •Positive test results indicating current or past infection with human immunodeficiency virus (HIV-1 or 2), hepatitis B virus (hepatitis B surface antigen [HBsAg], hepatitis B core antibody [anti-HBc]), or hepatitis C virus (HCV)
- •Positive screening test for latent mycobacterial infection within the 2 months preceding Day 1 without evidence of a completed course of anti-tubercular therapy or previous BCG vaccination
- •History of significant chronic or recurrent infections
- •History of clinically significant drug allergy and/or a known hypersensitivity to protein therapeutics or formulation components or a related drug
- •History of alcohol or drug abuse within 12 months prior to Day 1, or evidence of such abuse as indicated by the specific screening laboratory tests results, or alcohol consumption of more than 14 units of alcohol per week
- •Positive breathalyzer for alcohol or urine screen results for drugs of abuse, or prescription medications
- •Subjects who have previously received the study drug
- •Participation in a clinical trial within 4 weeks before Day 1 or use of any experimental or biologic therapy within the 12 weeks prior to Day 1 or within 5 half-lives of the product, whichever is greater
- •Use of prescription drugs within 14 days prior to Day 1 or during the study, except for hormonal contraceptives or hormone replacement therapy
- •Use of over-the-counter (OTC) medication within 7 days prior to Day 1 or during the study. Medications such as acetaminophen and ibuprofen and routinely-taken dietary supplements, including vitamins and herbal supplements are allowed at the discretion of the investigator and provided that the medication in question has no discernible impact on the study.
- •Donation of plasma within 7 days prior to Day
- •Donation or loss of blood of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to Day
- •Lack of peripheral venous access
- •Known history of mental illness
研究组 & 干预措施
A
Experimental
干预措施: MCAF5352A (Drug)
B
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: up to approximately 100 days
次要结局
- Pharmacokinetic: apparent clearance (CL/F)(up to approximately 100 days)
- Pharmacokinetic: maximum serum concentration (Cmax)(up to approximately 100 days)
- Pharmacokinetic: Terminal half-life (t½)(up to approximately 100 days)
- Pharmacokinetic: time to maximum serum concentration (tmax)(up to approximately 100 days)
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy SubjectsOligozoospermiaAsthenozoospermiaNCT06563713Staidson (Beijing) Biopharmaceuticals Co., Ltd40
已完成
1 期
Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple DosesHealthy VolunteerNCT03735810RBP4 Pty Ltd71
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With ObesityNCT06679959Ascletis Pharma (China) Co., Limited115
已完成
1 期
A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy SubjectsHealthy VolunteerNCT03627845pH Pharma49
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsHealthy ParticipantNCT05450549Denali Therapeutics Inc.47